Dato-DXd Did Not Achieve Statistically Significant OS in Patients With Breast Cancer
September 24th 2024Compared with chemotherapy, datopotamab deruxtecan (Dato-DXd) did not achieve a statistically significant overall survival (OS) in patients with inoperable or metastatic HR+/HER2-low or negative breast cancer.
Read More